<p id="thickbox_headline">The US Food and Drug Administration on Tuesday amended the fact sheet for Johnson & Johnson's Covid-19 vaccine to include a rare risk of immune thrombocytopenia, a bleeding disorder.</p>.<p>"Reports of adverse events following use of the Janssen Covid-19 vaccine under emergency use authorization suggest an increased risk of immune thrombocytopenia during the 42 days following vaccination," the regulator said in a letter to J&J's arm, Janssen Biotech Inc.</p>.<p>The symptoms include easy bruising or tiny blood spots under the skin, or unusual or excessive bleeding, the FDA said.</p>.<p>The amendment fact sheet follows similar moves for the vaccine by other regulators, including that of European Medicines Agency in October.</p>.<p>Both the J&J and AstraZeneca vaccines, which are based on a similar platform, have previously been associated with another very rare combination of blood clotting and low platelet counts, known as thrombosis with thrombocytopenia syndrome.</p>.<p>The US Centers for Disease Control and Prevention had also last month recommended Americans choose to receive one of two other authorized Covid-19 vaccines from Pfizer-BioNTech over J&J's single-dose shot, due to the rare but sometimes fatal risk. </p>.<p><strong>Watch the latest DH videos:</strong></p>
<p id="thickbox_headline">The US Food and Drug Administration on Tuesday amended the fact sheet for Johnson & Johnson's Covid-19 vaccine to include a rare risk of immune thrombocytopenia, a bleeding disorder.</p>.<p>"Reports of adverse events following use of the Janssen Covid-19 vaccine under emergency use authorization suggest an increased risk of immune thrombocytopenia during the 42 days following vaccination," the regulator said in a letter to J&J's arm, Janssen Biotech Inc.</p>.<p>The symptoms include easy bruising or tiny blood spots under the skin, or unusual or excessive bleeding, the FDA said.</p>.<p>The amendment fact sheet follows similar moves for the vaccine by other regulators, including that of European Medicines Agency in October.</p>.<p>Both the J&J and AstraZeneca vaccines, which are based on a similar platform, have previously been associated with another very rare combination of blood clotting and low platelet counts, known as thrombosis with thrombocytopenia syndrome.</p>.<p>The US Centers for Disease Control and Prevention had also last month recommended Americans choose to receive one of two other authorized Covid-19 vaccines from Pfizer-BioNTech over J&J's single-dose shot, due to the rare but sometimes fatal risk. </p>.<p><strong>Watch the latest DH videos:</strong></p>